



Max Sherman, PhD
Co-founder and CTO
Serinus Biosciences, Inc.

*Knowledge-primed AI to Power the Design of Rational
Combination Therapies*

Max Sherman is the co-founder and CTO of Serinus Biosciences, Inc., a biotechnology startup building an integrated computational and experimental platform to design safe and effective combination therapies for cancer patients. Fueled by his background in medicine and mathematics, Max's research focuses on uniting deep-learning and statistics to build approaches customized for the unique characteristic of biomedical data. The goal of his work is to extract actionable insights from next-generation genomics data that can inform therapeutic development and patient care.

Max has a PhD in Computer Science from MIT where he studied under computational biology pioneer Bonnie Berger and statistical geneticist Po-Ru Loh. Prior to his PhD, he studied statistics at the University of Cambridge and applied mathematics and biology at Brown University and worked as a statistician at Harvard Medical School.

Max's research has appeared in high-impact journals including Science, Cell, Nature Biotechnology, Nature Genetics, and Nature Neuroscience. His work has been recognized with awards from the American Society of Human Genetics, European Association of Cancer Research, and the National Institutes of Health.